Residency · Residency · Urology

Venous Thromboembolism Prophylaxis in Urologic Surgery

Introduction

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of preventable morbidity and mortality among surgical patients. Patients undergoing urologic surgery have varying risks of VTE depending on the specific procedure, their underlying comorbidities, and the presence of cancer. Pulmonary embolism remains one of the most frequent causes of postoperative death following major urologic surgeries. Therefore, implementing risk-stratified prophylaxis protocols is essential for patient safety and is a critical responsibility for every urologic surgeon.

Pathophysiology: Virchow's Triad

The development of VTE is explained by Virchow's triad, which consists of three primary factors. First, venous stasis occurs due to prolonged immobility, intraoperative positioning such as lithotomy or Trendelenburg, and the effects of pneumoperitoneum during laparoscopic procedures. Second, endothelial injury arises from surgical trauma, venous compression, or catheterization. Third, hypercoagulability is influenced by factors such as malignancy—particularly genitourinary cancers—hormonal therapy, inherited thrombophilias, obesity, prior VTE, and advanced age. These three components collectively contribute to the increased risk of thrombosis in surgical patients.

VTE Risk Assessment

Patient-Related Risk Factors

Among patient-related factors, malignancy stands out as the strongest independent risk factor, increasing VTE risk by four to seven times. A history of prior VTE also significantly elevates the risk of recurrence by two to three times. Obesity, defined as a body mass index (BMI) greater than 30, and advanced age over 60 years further contribute to risk. Inherited thrombophilias such as Factor V Leiden mutation, prothrombin G20210A mutation, protein C or S deficiency, and antithrombin III deficiency also predispose patients to thrombosis. Hormonal therapies, including androgen deprivation therapy and estrogen replacement, increase risk, as do smoking, heart failure, inflammatory bowel disease, and nephrotic syndrome.

Procedure-Related Risk Factors

The type of urologic procedure significantly influences VTE risk. Major open pelvic surgeries, such as radical cystectomy and radical prostatectomy, carry the highest risk, with symptomatic VTE rates ranging from 2 to 5% in the absence of prophylaxis. Radical nephrectomy involving inferior vena cava (IVC) tumor thrombus and pelvic lymph node dissection also increase risk. Prolonged operative times exceeding two hours further elevate the likelihood of thrombosis. Laparoscopic and robotic procedures introduce additional risk factors due to pneumoperitoneum, which reduces venous return, and steep Trendelenburg positioning, which promotes venous stasis in the lower extremities. Conversely, minor ambulatory procedures like cystoscopy and vasectomy pose minimal VTE risk.

Risk Stratification Tools

The Caprini Risk Assessment Model is a validated scoring system that assigns points to various risk factors to stratify patients into risk categories. Scores of 0 to 1 indicate very low risk, 2 corresponds to low risk, 3 to 4 indicates moderate risk, and scores of 5 or higher denote high risk. The American Urological Association (AUA) and the International Consultation on Urological Diseases (ICUD) guidelines recommend tailoring prophylaxis based on these risk categories, considering both the procedure and patient-specific factors.

<image>The Caprini Risk Assessment Model scoring tool showing common risk factors with their assigned point values, including age categories, BMI, malignancy, prior VTE, and surgical factors, with corresponding VTE prophylaxis recommendations for each risk category</image>

Prophylaxis Methods

Mechanical Prophylaxis

Intermittent pneumatic compression devices (IPCDs) function by sequentially inflating to promote venous return from the lower extremities. These devices should be applied before the induction of anesthesia and continued until the patient is fully ambulatory. IPCDs serve as first-line prophylaxis for low-risk patients and as an adjunct to pharmacologic prophylaxis in higher-risk individuals. They carry no bleeding risk but may be limited by patient compliance and tolerance. Graduated compression stockings (GCS) provide static compression ranging from 15 to 30 mmHg but are less effective than IPCDs when used alone. They are contraindicated in patients with severe peripheral arterial disease. Early ambulation is a fundamental component of VTE prevention and should be encouraged within 6 to 8 hours postoperatively whenever feasible.

Pharmacologic Prophylaxis

Unfractionated heparin (UFH) is administered subcutaneously at 5000 units every 8 to 12 hours. It has a short half-life of 1 to 2 hours and can be reversed with protamine sulfate, making it preferable for patients with significant renal impairment (creatinine clearance less than 30 mL/min). Low-molecular-weight heparin (LMWH), such as enoxaparin at 40 mg subcutaneously once daily, offers more predictable pharmacokinetics and improved compliance due to once-daily dosing. Dose adjustments are necessary for patients with creatinine clearance below 30 mL/min, typically reducing the dose to 30 mg daily. LMWH has demonstrated superiority over UFH for VTE prevention in cancer surgery patients. Fondaparinux, a selective factor Xa inhibitor given at 2.5 mg subcutaneously daily, serves as an alternative in cases of heparin-induced thrombocytopenia (HIT). Direct oral anticoagulants (DOACs), such as rivaroxaban 10 mg daily, are approved for post-surgical VTE prophylaxis in orthopedic surgery and have emerging evidence supporting their use in abdominal and pelvic surgeries.

Timing of Initiation

Pharmacologic prophylaxis can be initiated preoperatively or postoperatively. The European model favors administering LMWH 2 to 12 hours before surgery or UFH 2 hours prior, while the North American preference is to start LMWH 6 to 12 hours after surgery. Earlier initiation improves prophylactic efficacy but increases the risk of surgical bleeding. For urologic procedures with a high bleeding risk, postoperative initiation is generally preferred to balance these concerns.

Procedure-Specific Recommendations

Low-Risk Procedures (Caprini 0-2)

Procedures such as cystoscopy, ureteroscopy, vasectomy, circumcision, and minor scrotal surgeries fall into the low-risk category. For these patients, early ambulation combined with mechanical prophylaxis is recommended, while pharmacologic prophylaxis is generally not indicated.

Moderate-Risk Procedures (Caprini 3-4)

Transurethral resection of the prostate (TURP), transurethral resection of bladder tumor (TURBT), and laparoscopic nephrectomy without malignancy are considered moderate risk. Mechanical prophylaxis using IPCDs is advised, with or without pharmacologic prophylaxis. The addition of LMWH or UFH should be considered if other patient risk factors are present.

High-Risk Procedures (Caprini ≥5)

Radical cystectomy represents the highest VTE risk procedure in urology, with rates up to 8 to 11% without prophylaxis. Radical prostatectomy, whether open or robotic, and radical nephrectomy, especially when involving tumor thrombus, also carry high risk. For these patients, combined mechanical and pharmacologic prophylaxis is recommended, with LMWH preferred. Extended prophylaxis with LMWH for four weeks postoperatively is advised after major cancer surgeries such as radical cystectomy and radical nephrectomy with malignancy.

<image>Algorithm for VTE prophylaxis in urologic surgery showing three pathways based on procedure risk (low, moderate, high), with each pathway incorporating patient risk factors to determine final prophylaxis recommendation including mechanical devices, pharmacologic agents, duration, and extended prophylaxis considerations for cancer surgery</image>

Extended-Duration Prophylaxis

Extended prophylaxis for 28 days postoperatively is supported by evidence in patients undergoing major abdominal or pelvic cancer surgery. The ENOXACAN II trial demonstrated that four weeks of LMWH after major abdominal cancer surgery reduced VTE incidence from 12% to 4.8% compared to one week of prophylaxis. The AUA Best Practice Statement recommends extended prophylaxis following radical cystectomy and other major open cancer procedures. However, extended prophylaxis is typically not necessary for minimally invasive procedures with early discharge.

Special Populations

Patients with active cancer have a four to sevenfold increased risk of VTE. LMWH is preferred over UFH in this population, and extended prophylaxis should be considered for all major cancer operations. Patients undergoing chemotherapy carry additional VTE risk. Those with a history of prior VTE represent one of the strongest risk groups for recurrence and require aggressive prophylaxis using both mechanical and pharmacologic methods. In cases where anticoagulation is contraindicated, a retrievable inferior vena cava (IVC) filter may be considered. Obese patients may require weight-based dosing, as standard prophylactic doses can be inadequate; for example, enoxaparin 40 mg twice daily is recommended for patients with a BMI over 40. IPCDs should be appropriately sized for these patients. In individuals with renal impairment (creatinine clearance less than 30 mL/min), UFH is preferred over LMWH, but if LMWH is used, dose reduction and anti-Xa monitoring are advised.

Diagnosis and Management of Perioperative VTE

Diagnosis of DVT is typically made using lower extremity duplex ultrasound, and treatment involves therapeutic anticoagulation. Pulmonary embolism is diagnosed with CT pulmonary angiography. In cases of hemodynamically unstable PE, systemic thrombolysis or catheter-directed therapy may be necessary. Postoperative anticoagulation requires careful balancing of VTE treatment against the risk of surgical bleeding, necessitating multidisciplinary discussion. An IVC filter may be considered for patients with proximal DVT or PE who cannot receive anticoagulation.

Key Clinical Pearls

Radical cystectomy carries the highest risk of VTE among urologic procedures, and extended prophylaxis for four weeks postoperatively is the standard of care. Intermittent pneumatic compression devices should be applied before anesthesia induction and maintained until the patient is fully ambulatory. Low-molecular-weight heparin is superior to unfractionated heparin for VTE prophylaxis in cancer surgery patients. The Caprini score is a validated and practical tool for individualizing VTE prophylaxis in urologic patients. Despite the minimally invasive nature of robotic surgery, pneumoperitoneum and steep Trendelenburg positioning increase venous stasis, so one should not assume that these approaches eliminate VTE risk.

References

1. Pannucci CJ, Swistun L, MacDonald JK, et al. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients. Ann Surg. 2017;265(6):1094-1103.
2. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer (ENOXACAN II). N Engl J Med. 2002;346(13):975-980.
3. Forrest JB, Clemens JQ, Finamore P, et al. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urological surgery. J Urol. 2009;181(3):1170-1177.
4. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S-e277S.

Read this lecture as Markdown